Thorne HealthTech Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Thorne HealthTech heeft een totaal eigen vermogen van $155.3M en een totale schuld van $25.0M, wat de schuld-eigenvermogensverhouding op 16.1% brengt. De totale activa en totale passiva bedragen respectievelijk $282.5M en $127.3M. De EBIT Thorne HealthTech is $14.0M waardoor de rentedekking 14.8 is. Het heeft contanten en kortetermijnbeleggingen van $17.1M.

Belangrijke informatie

16.1%

Verhouding schuld/eigen vermogen

US$24.99m

Schuld

Rente dekkingsratio	14.8x
Contant	US$17.09m
Aandelen	US$155.26m
Totaal verplichtingen	US$127.27m
Totaal activa	US$282.53m

Recente financiële gezondheidsupdates

Recent updates

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Aug 12

Thorne HealthTech swings to Q2 Non-GAAP loss per share, revenue down Y/Y, FY22 guidance revised

Aug 09

Thorne HealthTech: Poised To Outperform Other Nutraceutical Companies

Jun 05

Shareholders Can Be Confident That Thorne HealthTech's (NASDAQ:THRN) Earnings Are High Quality

Mar 23

Thorne HealthTech: Good Potential At A Low Price

Jan 11

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $135.5M ) THRN } overtreffen de korte termijn passiva ( $56.2M ).

Langlopende schulden: De kortetermijnactiva THRN ( $135.5M ) overtreffen de langetermijnschulden ( $71.0M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 5.1% ) THRN wordt als voldoende beschouwd.

Schuld verminderen: Er zijn onvoldoende gegevens om te bepalen of de schuld/eigen vermogen-ratio van THRN de afgelopen 5 jaar is gedaald.

Schuldendekking: De schuld van THRN wordt goed gedekt door de operationele kasstroom ( 86.1% ).

Rentedekking: De rentebetalingen op de schuld van THRN worden goed gedekt door EBIT ( 14.8 x dekking).

Thorne HealthTech Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Thorne Healthtech, Inc. Files Form 15

Thorne HealthTech's Common Stock To Be Delisted from Nasdaq Global Select Market

Thorne HealthTech Receives Non-Compliance Notice from Nasdaq

Recent updates

Thorne Appoints Mary Beech as Chief Growth Officer

Thorne Healthtech, Inc. Files Form 15

Thorne HealthTech, Inc.(NasdaqGS:THRN) dropped from NASDAQ Composite Index

Thorne HealthTech's Common Stock To Be Delisted from Nasdaq Global Select Market

Thorne HealthTech Receives Non-Compliance Notice from Nasdaq

Price target increased by 11% to US$8.36

Thorne Healthtech, Inc. Announces Resignation of Takeshi Minakata from the Board of Directors

Investor sentiment improves as stock rises 27%

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Thorne Healthtech, Inc. Provides Earnings Guidance for 2023

Thorne HealthTech, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target increased by 8.7% to US$7.50

Thorne HealthTech Reportedly Working with Bank to Explore Sale

Investor sentiment improves as stock rises 17%

Thorne HealthTech, Inc. (NASDAQ:THRN) Not Flying Under The Radar

First quarter 2023 earnings: EPS misses analyst expectations

Thorne HealthTech, Inc. Reaffirms Financial Guidance for the Full-Year 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thorne HealthTech, Inc. (NasdaqGS:THRN) acquired PreCon Health, Inc. from Eigenlyfe LLC for $5 million.

Investor sentiment improves as stock rises 15%

Thorne HealthTech, Inc. Announces Executive Changes

Investors Will Want Thorne HealthTech's (NASDAQ:THRN) Growth In ROCE To Persist

Investor sentiment improved over the past week

Thorne Healthtech's OneDraw Device Used in Department of Defense's Cancer Moonshot 2.0 Project, Prometheus, as Part of President Biden Initiative

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$7.50

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Thorne HealthTech, Inc. Revises Net Sales Guidance for the Full Year 2022

Thorne HealthTech, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Thorne HealthTech Grows But Faces Macro Headwinds

Thorne Healthtech's OneDraw(TM) Blood Collection Device Receives PMDA Certification in Japan

Thorne HealthTech's blood collection device OneDraw gets clearance in Japan

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Thorne HealthTech, Inc. Revises Sales Guidance for the Full-Year 2022

Thorne HealthTech swings to Q2 Non-GAAP loss per share, revenue down Y/Y, FY22 guidance revised

Investor sentiment improved over the past week

Thorne HealthTech, Inc. Achieves Self-Affirmed GRAS Status for Nicotinamide Riboside Malate Product

Thorne HealthTech, Inc.(NasdaqGS:THRN) dropped from Russell 2500 Value Index

Thorne HealthTech: Poised To Outperform Other Nutraceutical Companies

Thorne HealthTech, Inc. Relaunches Gut Health Test

Thorne HealthTech, Inc. Relaunches Gut Health Test

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Thorne HealthTech, Inc. Reaffirms Sales Guidance for the Full-Year 2022

Thorne HealthTech, Inc., Annual General Meeting, Jun 02, 2022

Co-Founder exercised options to buy US$326k worth of stock.

Consensus forecasts updated

Shareholders Can Be Confident That Thorne HealthTech's (NASDAQ:THRN) Earnings Are High Quality

Full year 2021 earnings: EPS misses analyst expectations

Thorne HealthTech: Good Potential At A Low Price

Forecast breakeven date pushed back to 2022

Forecast to breakeven in 2021

Thorne HealthTech, Inc. has completed an IPO in the amount of $70 million.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven